Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | IDH1 | O75874 | 6/20 | 0.33 |
| ▸ | WHR1 | P49842 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844241 | 0.85 | MAPK10 (0.42) | PDE4BPDE7AMAPK1MEN1USP2 | |
| SCHEMBL17844225 | 0.85 | MAPK10 (0.42) | PDE4BPDE7AMAPK1MEN1USP2 | |
| SCHEMBL2000938 | 0.70 | GBA1 (0.35) | GBA1MAPK1IDH1WHR1FFAR2 | |
| SCHEMBL5185900 | 0.67 | KAT2B (0.36) | MEN1MAPTHTTKMT2AL3MBTL1 | |
| SCHEMBL28868824 | 0.67 | GBA1 (0.36) | GBA1MAPK1IDH1WHR1FFAR2 | |
| SCHEMBL17844146 | 0.66 | HTR1B (0.39) | MAPTL3MBTL1 | |
| SCHEMBL17844164 | 0.66 | KAT2B (0.38) | MAPK1 | |
| SCHEMBL5184355 | 0.66 | BRD4 (0.36) | MAPK1USP2MAPK8BRD4 | |
| SCHEMBL17844153 | 0.65 | MAPK8 (0.41) | MAPK1MEN1MAPTHTTKMT2A | |
| SCHEMBL31303190 | 0.64 | IDH1 (0.43) | GBA1IDH1FFAR2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | GBA1 807/4885PDE4B 2138/4885PDE7A 2340/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | GBA1 807/4885PDE4B 2138/4885PDE7A 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.